Safety profile of lacidipine. Update from a clinical trials database

Drugs

Volumn 57, Issue SUPPL. 1, 1999, Pages 27-29

  Lindholm, Lars H ^a   Tcherdakoff, Philippe ^b   Zanchetti, Alberto ^c  

^a UMEÅ UNIVERSITY   (Sweden)

^b Ospedale Maggiore ^*  (France)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; LACIDIPINE;

ASTHENIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; EDEMA; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; SKIN MANIFESTATION; VERTIGO;

AGED; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III; CLINICAL TRIALS, PHASE IV; DATABASES, FACTUAL; DIHYDROPYRIDINES; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0032821883     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957001-00004     Document Type: Conference Paper

References (10)

1. MacMahon S, Peto R, Cutler J. et al. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74
2. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38
3. Lindholm LH, Hansson L, Dahlöf B, et al. The Swedish Trial in Old Patients with Hypertension-2 (STOP-Hypertension-2): a progress report. Blood Press 1996; 5: 300-4
4. Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Press 1997; 6 (5): 313-7
5. Zanchetti A, Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in The Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). J Hynertens 1995; 13 Suppl. 13: 535-9
6. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5
7. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1329-31
8. Lindholm LH, Tcherdakoff P, Zanchetti A. Safety of the calcium antagonist lacidipine evaluated from a phase III-IV trial database. J Hypertens 1996; 14 Suppl. 2: S15-20
9. Cutler J, Psaty BM, MacMahon S, et al. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press, 1995; 253-70
10. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison, of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64